Abstract
Glycoprotein (GP) IIb\IIIa receptor plays a central role on platelets activation and its blockage has been a matter of interest since the beginning of percutaneous revascularization. After first promising trials, GP IIb\IIIa inhibitors (GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment Elevation Myocardial Infarction (STEMI). However, their utilization isn’t exempt from risks, mainly in form of bleeding disorders, which can negatively affect patients’ outcome. Moreover, routinary administration of thyenopiridines like clopidogrel and the introduction of new anticoagulants like bivalirudin significantly reduced indications for GPI. In this review, a risk/benefit evaluation GP IIb\IIIa inhibitors is presented and their indications for STEMI patients addressed to revascularization are discussed according to recent advances reported in literature.
Keywords: STEMI, glycoprotein IIb\IIIa, abcximab, eptifibatide, tirofiban, clopidogrel, bivalirudin, anticoagulants, bleeding disorders
Current Vascular Pharmacology
Title:GP IIb/IIIa Inhibitors for STEMI: Still the Gold Standard or an Old Survivor?
Volume: 10 Issue: 4
Author(s): Giuseppe Musumeci, Matteo Baroni and Roberta Rossini
Affiliation:
Keywords: STEMI, glycoprotein IIb\IIIa, abcximab, eptifibatide, tirofiban, clopidogrel, bivalirudin, anticoagulants, bleeding disorders
Abstract: Glycoprotein (GP) IIb\IIIa receptor plays a central role on platelets activation and its blockage has been a matter of interest since the beginning of percutaneous revascularization. After first promising trials, GP IIb\IIIa inhibitors (GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment Elevation Myocardial Infarction (STEMI). However, their utilization isn’t exempt from risks, mainly in form of bleeding disorders, which can negatively affect patients’ outcome. Moreover, routinary administration of thyenopiridines like clopidogrel and the introduction of new anticoagulants like bivalirudin significantly reduced indications for GPI. In this review, a risk/benefit evaluation GP IIb\IIIa inhibitors is presented and their indications for STEMI patients addressed to revascularization are discussed according to recent advances reported in literature.
Export Options
About this article
Cite this article as:
Musumeci Giuseppe, Baroni Matteo and Rossini Roberta, GP IIb/IIIa Inhibitors for STEMI: Still the Gold Standard or an Old Survivor?, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812737
DOI https://dx.doi.org/10.2174/157016112800812737 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology Diabetic Vasculopathy and the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1)
Current Diabetes Reviews Dietary Phytonutrients in the Prevention of Diabetes-related Complications
Current Diabetes Reviews Development and Current Applications of Thrombin-specific Inhibitors
Current Drug Targets - Cardiovascular & Hematological Disorders Alteration of Isocitrate Dehydrogenase Following Acute Ischemic Injury as a Means to Improve Cellular Energetic Status in Neuroadaptation
CNS & Neurological Disorders - Drug Targets Interactive Effect of Combined Exposure to Active and Passive Smoking on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Poly (ADP-Ribose) Polymerase Inhibitors as Potential Therapeutic Agents in Stroke and Neurotrauma
Current Drug Targets - CNS & Neurological Disorders Cardiovascular Effects of Glucagon-Like Peptide 1
Mini-Reviews in Medicinal Chemistry ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Extracranial-to-Intracranial Bypass for Pressor Dependent Cerebrovascular Insufficiency: Modified Classification and Representative Case
Current Neurovascular Research Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes
Current Hypertension Reviews Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs
Current Pharmaceutical Design Current Advances in the Biological Activity of Polysaccharides in Dendrobium with Intriguing Therapeutic Potential
Current Medicinal Chemistry Ximelagatran - A Promising New Drug in Thromboembolic Disorders
Current Pharmaceutical Design Nutrition and Nutraceuticals in Neuroinflammatory and Brain Metabolic Stress: Implications for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Non-Invasive Imaging of Human Embryonic Stem Cells
Current Pharmaceutical Biotechnology Serum Thyroid Peroxidase Antibody Level and Incident Hypertension in Iranian Men: A Suggestion for the Role of Thyroid Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Granulocyte Apoptosis and Macrophage Clearance of Apoptotic Cells as Targets for Pharmacological Intervention in Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry